What we do
APIs and Intermediates:
We are a specialized pharma company focusing on niche therapeutic areas of CNS,
ARVs and controlled substances. Our specialization in unique CNS segments like ADHD,
Anti-psychotics, Anti-vertigo, Anti-inflammatory, Pain management, Alzheimer disease
and others gives ZCL the leverage to outclass the competition. We are moving up
the value chain adding capacity for more APIs.
CMO:
With the best in class manufacturing facilities with accreditation and state-of-the-art
research platform besides brilliant minds in our R&D we have embarked on establishing
contract manufacturing organization. We have many on-going contract manufacturing
projects that involve complex chemistry and technological excellence.
Active Pharma Ingredients (APIs)
|
Product
|
Status
|
Pharmacoepeia
|
CAS No.
|
Therapeutic Use
|
Enquiry
|
|
Alprazolam
|
Tech pack
|
USP/EP
|
28981-97-7
|
Anxiolytic
|
|
|
Aripiprazole
|
USDMF⁺, CEP, KDMF
|
USP/EP
|
129722-12-9
|
Anti-depressant/Anti-psychotic
|
|
|
Atomoxetine HCl
|
CEP, USDMF, TDMF, IDL*
|
USP/EP
|
82248-59-7
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Betahistine Dihydrochloride
|
CEP, TDMF, CA-DMF
|
USP/BP/EP/IP
|
5579-84-0
|
Vertigo
|
|
|
Clozapine
|
USDMF⁺, CEP*
|
USP/EP/IP
|
5786-21-0
|
Anti-psychotic
|
|
|
Dapagliflozin propanediol monohydrate
|
Tech pack
|
Inhouse
|
960404-48-2
|
Anti-diabetic
|
|
|
Darunavir ethanolate
|
Tech pack
|
Inhouse
|
635728-49-3
|
Treatment of AIDS and HIV infections
|
|
|
Dexmethylphenidate HCl
|
Tech pack
|
Inhouse
|
19262-68-1
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Empagliflozin
|
Tech pack
|
In-house
|
864070-44-0
|
Anti-diabetic
|
|
|
Eslicarbazepine Acetate
|
USDMF*, EDMF*
|
In-house/IP
|
236395-14-5
|
Anti-epileptic
|
|
|
Felbinac
|
EDMF, JDMF*
|
BP/EP/JP
|
5728-52-9
|
Anti-inflammatory
|
|
|
Fluvoxamine Maleate
|
CEP, USDMF⁺, TDMF
|
USP/BP/EP/IP
|
61718-82-9
|
Anti-depressant
|
|
|
Levomepromazine Maleate
|
CEP*
|
EP/JP
|
7104-38-3
|
Anti-psychotic
|
|
|
Lurasidone HCl
|
USDMF⁺
|
In-house
|
367514-88-3
|
Anti-psychotic
|
|
|
Memantine HCl
|
USDMF, AUSDMF
|
USP
|
41100-52-1
|
Alzheimer Disease
|
|
|
Methylphenidate HCl
|
CEP
|
USP/EP
|
298-59-9
|
Attention Deficit Hyperactivity Disorder (ADHD)
|
|
|
Mirabegron
|
Tech pack
|
In-house
|
223673-61-8
|
Treatment of overactive bladder
|
|
|
Modafinil
|
Tech pack
|
USP/EP
|
68693-11-8
|
CNS Stimulant
|
|
|
Olanzapine
|
Tech pack
|
USP
|
132539-06-1
|
Anti-psychotic
|
|
|
Phenylephrine hydrochloride
|
Tech pack
|
EP/IP
|
61-76-7
|
Decongestant
|
|
|
Pirfenidone
|
USDMF*, CEP
|
EP/IP
|
53179-13-8
|
Anti-Inflammatory / Anti-Rheumatic
|
|
|
Pregabalin
|
Tech pack
|
In-house
|
148553-50-8
|
Epilepsy, Neuropathic pain and generalized anxiety disorder
|
|
|
Quetiapine Fumarate
|
USDMF⁺, AUSDMF, CEP
|
USP/EP
|
111974-72-2
|
Anti-psychotic
|
|
|
Rivaroxaban
|
USDMF
|
In-house
|
366789-02-8
|
Anti-coagulant
|
|
|
Trifluoperazine HCl
|
Tech pack
|
USP/BP/EP/IP
|
440-17-5
|
Anti-psychotic
|
|
|
Zaltoprofen
|
KDMF
|
JP
|
74711-43-6
|
Anti-inflammatory
|
|
|
Zonisamide
|
USDMF
|
USP
|
68291-97-4
|
Anti-convulsant
|
|
|
|
|
Product Pipeline / Under evaluation
|
|
Apixaban
|
Under development
|
In-house
|
503612-47-3
|
Anticoagulant
|
|
|
Betrixaban
|
Under evaluation
|
In-house
|
330942-05-7
|
Anticoagulant
|
|
|
Dabigatran Etexilate Mesylate
|
Under evaluation
|
In-house
|
872728-81-9
|
Anticoagulant
|
|
|
Ertugliflozin
|
Under evaluation
|
In-house
|
1210344-57-2
|
Anti-diabetic
|
|
|
Sitagliptin
|
Under evaluation
|
In-house
|
486460-32-6
|
Anti-diabetic
|
|
|
Ticagrelor
|
Under evaluation
|
In-house
|
274693-27-5
|
Platelet aggregation inhibitor
|
|
|
Trimebutine Maleate
|
Under evaluation
|
In-house
|
34140-59-5
|
Antimuscarinic
|
|
|
Varenicline Tartrate
|
Under evaluation
|
In-house
|
249296-44-4
|
Anti smoking
|
|
|
Vildagliptin
|
Under evaluation
|
In-house
|
274901-16-5
|
Anti diabetic
|
|
* Under filing, + DMF Info Available for Reference
Disclaimer:
All transactions are carried out in conformity with the patent laws applicable in
the user country.
Responsibility with respect to third partie’s patent rights in a specific country
lies exclusively with the buyer.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC ¶ 271
(e) (1)
Advanced Intermediates
|
Product
|
CAS No.
|
End Use
|
Structure
|
Enquiry
|
|
1-(2,3-Dichlorophenyl) Piperazine HCl
|
119532-26-2
|
Aripiprazole
|
|
|
|
N-Benzhydrylpiperazine
|
841-77-0
|
Cinnarizine
|
|
|
|
Benzenesulfonamide, 4-amino-N-[(2R,3S)-3-amino-2- hydroxy-4-phenylbutyl]-N-(2-methylpropyl)
|
169280-56-2
|
Darunavir
|
|
|
|
Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-
(phenylmethyl)propyl]-,1,1-dimethylethylester
|
191226-98-9
|
Darunavir, Fosamprenavir
|
|
|
|
(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide
|
104746-04-5
|
Eslicarbazepine acetate
|
|
|
|
10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
|
29331-92-8
|
Eslicarbazepine acetate
|
|
|
|
4,4'-Difluorobenzhydrylpiperazine
|
27469-60-9
|
Flunarizine
|
|
|
|
(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine
|
61747-22-6
|
Fluvoxamine
|
|
|
|
2-Bromo-4'-benzyloxy-3'-nitroacetophenone
|
43229-01-2
|
Formoterol
|
|
|
|
2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one
|
252964-68-4
|
Itraconazole
|
|
|
|
1-Acetyl-4-(4-hydroxyphenyl) piperazine
|
67914-60-7
|
Ketoconazole
|
|
|
|
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
|
68767-14-6
|
Loxoprofen Sodium
|
|
|
|
1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol hydrochloride
|
521284-22-0
|
Mirabegron
|
|
|
|
(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol
|
223673-34-5
|
Mirabegron
|
|
|
|
2-Methyl-10H-thieno[2,3-b][1,5] benzo diazepine-4-amine HCl
|
138564-60-0
|
Olanzapine
|
|
|
|
5-methyl-2-(2-nitrophenylamino) thiophene-3-carbonitrile
|
138564-59-7
|
Olanzapine
|
|
|
|
(R)-(-)-3-Carbamoylmethyl-5-methylhexanoic acid
|
181289-33-8
|
Pregabalin
|
|
|
|
5-methylpyridin-2(1H)-one (synonym : 2-Hydroxy-5-methylpyridine)
|
1003- 68-5
|
Pirfenidone
|
|
|
|
1-Aminoindan
|
34698-41-4
|
Rasagiline
|
|
|
|
4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride
|
898543-06-1
|
Rivaroxaban
|
|
|
|
2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione
|
446292-08-6
|
Rivaroxaban
|
|
|
|
N-Isopropyl-4-(4-hydroxyphenyl)-piperazine
|
67914-97-0
|
Terconazole
|
|
|
|
2-(Trifluoromethyl)-phenothiazine
|
92-30-8
|
Trifluoperazine
|
|
|
Disclaimer:
All transactions are carried out in conformity with the patent laws applicable in
the user country.
Responsibility with respect to third partie’s patent rights in a specific country
lies exclusively with the buyer.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC ¶ 271
(e) (1)
Under Scale-up / New Development
|
Product
|
CAS No.
|
End Use
|
Status
|
Structure
|
Enquiry
|
|
1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate,
(1S)- D-Glucitol
|
461432-25-7
|
Dapagliflozin propanediol
|
Under development
|
|
|
|
4-Amino-2-fluoro-N-methylbenzamide
|
915087-25-1
|
Apalutamide,Enzalutamide
|
Underscale-up
|
|
|
|
N-Methyl-2-fluoro-4-(1,1-dimethyl cyanomethyl) aminobenzamide
|
915087-32-0
|
Enzalutamide
|
Under scaleup
|
|
|
|
(5-bromo-2-chlorophenyl)(4-fluorophenylmethanone
|
915095-85-1
|
Empagliflozin
|
Under development
|
|
|
|
(S)-(5-bromo-2-chlorophenyl)(4-((tetrahydrofuran-3-yl) oxy)phenyl)methanone
|
915095-84-0
|
Empagliflozin
|
Under development
|
|
|
|
(3S)-3-[4-[(5-Bromo-2-chlorophenyl)methyl]phenoxy]tetrahydrofuran
|
915095-89-5
|
Empagliflozin
|
Under development
|
|
|
|
(2R,3R,4R,5S,6S)-2- (acetoxymethyl)-6-(4-chloro- 3-(4-(((S)-tetrahydrofuran3-yl)oxy)benzyl)phenyl)tetrahy
dro-2H-pyran-3,4,5-triyl triacetate
|
915095-99-7
|
Empagliflozin
|
Under development
|
|
|
|
5-Bromo-2-chloro-4'ethoxydiphenylmethane
|
461432-23-5
|
Dapagliflozin
|
Under scale-up
|
|
|
|
2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone
|
32384-65-9
|
Dapagliflozin,Empagliflozin
|
Under development
|
|
|
*USDMF available
Disclaimer:
All transactions are carried out in conformity with the patent laws applicable in
the user country.
Responsibility with respect to third partie’s patent rights in a specific country
lies exclusively with the buyer.
The therapeutic use shown against each product is indicative only and is not for
advertising ZCL products.
Patented Products are available for R&D use as per permitted under 35 USC ¶ 271
(e) (1)
Disclaimer
Information given herein is offered in good faith as accurate, but without guarantee.
Conditions of use and suitability of the product for particular uses are beyond
our control. All risks of use of the product are therefore assumed by the user.
ZCL Chemicals Limited EXPRESSLY DISCLAIMS ALL WARRANTIES OF EVERY KIND AND NATURE,
INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE IN
RESPECT TO THE USE OR SUITABILITY OF THE PRODUCT. Appropriate warnings and safe
handling procedures should be provided to handlers and users.
Alteration of this document is strictly prohibited.
No statement contained herein concerning a possible or suggested use of any material,
product or design is intended, or should be construed, to grant any license under
any patent or other intellectual property right of ZCL Chemicals Limited or any
of its associates or its affiliates covering such use or design, or as a recommendation
for the use of such material, product or design in the infringement of any patent
or other intellectual property right. The products are sold subject to ZCL Chemicals
Limited Standard Conditions of Sale, which are available upon request.